☆ 4.7 Meeting Abstract

A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma

ANNALS OF ONCOLOGY (2016)

期刊

ANNALS OF ONCOLOGY

卷 27, 期 -, 页码 -

出版社

OXFORD UNIV PRESS

DOI: 10.1093/annonc/mdw379.42

关键词

-

类别

Oncology

资金

Celldex Therapeutics, Inc.

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Biochemistry & Molecular Biology

An auristatin-based antibody-drug conjugate targeting EphA2 in pancreatic cancer treatment

Fu-Ling Chang, Cheng-Chung Lee, Keng-Chang Tsai, Tsai-Yu Lin, Chen-Wei Chiang, Shiow-Lin Pan, Yu-Ching Lee

Summary: In this study, a novel antibody-drug conjugate (ADC) specifically targeting EphA2 in pancreatic cancer cells was developed. The ADC showed impressive tumor-killing response, inhibiting tumor cell growth and promoting apoptosis. The results suggest the potential of further developing the ADC to have a broader and more potent therapeutic impact on pancreatic cancer and other EphA2-related cancers.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2023)

添加到收藏夹

Editorial Material Hematology

United we stand: Double targeting of CD79B and CD20 in diffuse large B-cell lymphoma

Chiara Tarantelli, Francesco Bertoni

Summary: This article discusses the molecular basis of the combination of polatuzumab vedotin and rituximab in the treatment of diffuse large B-cell lymphoma, and provides clues to the potential mechanisms of resistance to this combination therapy.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

GPNMB: a potent inducer of immunosuppression in cancer

Anna-Maria Lazaratos, Matthew G. Annis, Peter M. Siegel

Summary: GPNMB plays an immunosuppressive role in cancer by promoting tumor growth and metastasis, and its expression is associated with poor prognosis. It regulates cancer progression by restraining immune responses.

ONCOGENE (2022)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Targeted Treatment of Locally Advanced and Metastatic Urothelial Cancer: Enfortumab Vedotin in Context

Jean Hoffman-Censits, Laneisha Maldonado

Summary: Enfortumab vedotin (EV) is a novel antibody-drug conjugate that has been FDA-approved for the treatment of treatment-refractory urothelial cancer. It has shown high activity in patients with poor prognosis, and has a good tolerability profile. Ongoing trials are exploring its use in different disease states and in combination with other agents.

ONCOTARGETS AND THERAPY (2022)

添加到收藏夹

Article Oncology

Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer

Tanya Jindal, Xiaolin Zhu, Rohit Bose, Vipul Kumar, Edward Maldonado, Prianka Deshmukh, Chase Shipp, Stephanie Feng, Michelle S. Johnson, Austin Angelidakis, Daniel Kwon, Hala T. Borno, Ivan de Kouchkovsky, Arpita Desai, Rahul Aggarwal, Lawrence Fong, Eric J. Small, Anthony Wong, Sima Porten, Jonathan Chou, Terence Friedlander, Vadim S. Koshkin

Summary: In this study, the NGS data of aUC patients treated with EV monotherapy were retrospectively analyzed. It was found that patients with TP53, KDM6A, and MDM2 gene alterations had a higher response rate to EV treatment. Furthermore, baseline albumin level lower than 3.0g/dL and composite TP53/MDM2 gene alterations were associated with patient survival outcomes. Prospective and external validation in larger cohorts is needed.

FRONTIERS IN ONCOLOGY (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin

Marco Biondini, Alex Kiepas, Leeanna El-Houjeiri, Matthew G. An Nis, Brian E. Hsu, Anne-Marie Fortier, Genevieve Morin, Jose A. Martina, Isabelle Sirois, Adriana Aguilar-Mahecha, Tina Gruosso, Shawn McGuirk, April A. N. Rose, Unal M. Tokat, Radia M. Johnson, Ozgur Sahin, Eric Bareke, Julie St-Pierre, Morag Park, Mark Basik, Jacek Majewski, Rosa Puertollano, Arnim Pause, Sidong Huang, Tibor Keler, Peter M. Siegel

Summary: This study found that GPNMB is associated with the prognosis of TNBC, and the combination of HSP90 inhibitor and Glembatumumab Vedotin can increase the cell-surface localization of GPNMB and enhance its efficacy.

ONCOGENE (2022)

添加到收藏夹

Review Oncology

Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?

Brigida Anna Maiorano, Martina Catalano, Evaristo Maiello, Giandomenico Roviello

Summary: Enfortumab vedotin (EV) is a promising treatment for metastatic urothelial carcinoma (mUC), showing good efficacy and survival improvement in a setting with limited treatment options. It has the potential to become an effective treatment option for mUC patients.

FRONTIERS IN ONCOLOGY (2023)

添加到收藏夹

Article Oncology

DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo

Joan Tymon-Rosario, Elena Bonazzoli, Stefania Bellone, Aranzazu Manzano, Silvia Pelligra, Adele Guglielmi, Barbara Gnutti, Nupur Nagarkatti, Burak Zeybek, Paola Manara, Luca Zammataro, Justin Harold, Dennis Mauricio, Natalia Buza, Pei Hui, Gary Altwerger, Gulden Menderes, Elena Ratner, Mitchell Clark, Vaagn Andikyan, Gloria S. Huang, Dan-Arin Silasi, Masoud Azodi, Peter E. Schwartz, Alessandro D. Santin

Summary: The study evaluated the preclinical activity of DHES0815A against primary USC cell lines and xenografts, finding that DHES0815A is highly selective and toxic to USC tumors overexpressing HER2/neu.

GYNECOLOGIC ONCOLOGY (2021)

添加到收藏夹

Review Immunology

Therapeutic strategies targeting folate receptor a for ovarian cancer

Jia Mai, Limei Wu, Ling Yang, Ting Sun, Xiaojuan Liu, Rutie Yin, Yongmei Jiang, Jinke Li, Qintong Li

Summary: Epithelial ovarian cancer is a deadly gynecological cancer, and targeting the folate receptor alpha has shown promise in its treatment. Various modalities, including antibody-drug conjugates, monoclonal antibodies, and small molecules, have been explored to exploit this target for effective therapy.

FRONTIERS IN IMMUNOLOGY (2023)

添加到收藏夹

Article Oncology

Real-world effectiveness and safety of RC48-ADC alone or in combination with PD-1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study

Jingwei Xu, Hongqiao Zhang, Li Zhang, Xiufeng Chu, Yu Li, Guangyuan Li, Caiyun Nie, Meng Wang, Yanwei Guo

Summary: This study found that RC48-ADC, either as monotherapy or in combination with PD-1 inhibitors, exhibits promising effectiveness and manageable safety profile for mUC patients in real-world settings.

CANCER MEDICINE (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

Antibody-drug conjugates targeting CD248+ myofibroblasts effectively alleviate renal fibrosis in mice

Chao Xu, Shaojie Liu, Fa Yang, Keying Zhang, Yu Li, Xiaolong Zhao, Jiayu Zhang, Tong Lu, Shiqi Lu, Yao Jiang, Weijun Qin, Changhong Shi, Rui Zhang, An-Gang Yang, Aizhi Zhao, Donghui Han, Weihong Wen

Summary: The study revealed that CD248 can serve as a specific marker for myofibroblasts, and targeting CD248(+) myofibroblasts with an antibody-drug conjugate showed excellent anti-fibrotic effects in mice models.

FASEB JOURNAL (2022)

添加到收藏夹

Article Medicine, Research & Experimental

Macrolide and Ketolide Antibiotics Inhibit the Cytotoxic Effect of Trastuzumab Emtansine in HER2-Positive Breast Cancer Cells: Implication of a Potential Drug-ADC Interaction in Cancer Chemotherapy

Keisuke Kiyomiya, Ryuto Tomabechi, Naoki Saito, Kenta Watai, Tappei Takada, Yoshiyuki Shirasaka, Hisanao Kishimoto, Kei Higuchi, Katsuhisa Inoue

Summary: Macrolide and ketolide antibiotics can attenuate the cytotoxicity of HER2-targeting antibody-drug conjugate T-DM1 by accumulating in the lysosomes and inhibiting the function of SLC46A3, resulting in potential drug-ADC interaction during cancer chemotherapy.

MOLECULAR PHARMACEUTICS (2023)

添加到收藏夹

Review Oncology

Targeting CLDN18.2 in cancers of the gastrointestinal tract: New drugs and new indications

Jinxia Chen, Zhiyuan Xu, Can Hu, Shengjie Zhang, Mengli Zi, Li Yuan, Xiangdong Cheng

Summary: This review focuses on the expression pattern and clinical significance of CLDN18.2 in gastrointestinal cancers. It also discusses the tumour-promoting and/or tumour-inhibiting functions of CLDN18.2, the mechanisms regulating its expression, and the current progress in the development of drugs targeting CLDN18.2 in clinical research.

FRONTIERS IN ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Japanese subgroup analysis of EV-301: An open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma

Nobuaki Matsubara, Junji Yonese, Takahiro Kojima, Haruhito Azuma, Hiroaki Matsumoto, Thomas Powles, Jonathan E. Rosenberg, Daniel P. Petrylak, Maria Matsangou, Chunzhang Wu, Mary Campbell, Mayumi Yamashiro

Summary: Enfortumab vedotin has shown significant overall survival benefit for patients with advanced urothelial carcinoma, including in the Japanese population. It has consistent efficacy and safety, making it an important treatment option for previously treated patients with this condition.

CANCER MEDICINE (2023)

添加到收藏夹

Article Oncology

Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma

Charlene M. Mantia, Guru Sonpavde

Summary: Enfortumab vedotin-ejfv has shown promising efficacy and safety in pretreated patients with advanced urothelial carcinoma, and currently being evaluated in clinical trials in earlier lines of treatment and in combination therapy.

EXPERT REVIEW OF ANTICANCER THERAPY (2022)

添加到收藏夹

Article Oncology

Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors

Jason J. Luke, Fabrice Barlesi, Ki Chung, Anthony W. Tolcher, Karen Kelly, Antoine Hollebecque, Christophe Le Tourneau, Vivek Subbiah, Frank Tsai, Steven Kao, Philippe A. Cassier, Mustafa Khasraw, Hedy L. Kindler, Hua Fang, Frances Fan, Kathryn Allaire, Maulik Patel, Shiming Ye, Debra T. Chao, William R. Henner, Joel S. Hayflick, Michael A. McDevitt, Lawrence Fong

Summary: The study found that ABBV-428 monotherapy demonstrated dose-proportional pharmacokinetics and an acceptable safety profile, particularly in relation to toxicities associated with CD40 agonism. This indicates that utilizing a tumor-targeted, bispecific antibody can enhance the safety of CD40 agonism as a therapeutic approach.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Article Oncology

First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors

George D. Demetri, Jason J. Luke, Antoine Hollebecque, John D. Powderly, Alexander Spira, Vivek Subbiah, Louie Naumovski, Chris Chen, Hua Fang, Dominic W. Lai, Huibin Yue, Akshanth R. Polepally, James W. Purcell, Randy Robinson, Padmanee Sharma, James P. Allison, Anthony Tolcher, Victor M. Villalobos

Summary: LRRC15 is a potential therapeutic target expressed in stromal fibroblasts in various solid tumor microenvironments, especially in sarcoma patients. ABBV-085, a LRRC15-targeting antibody-drug conjugate, demonstrated preliminary antitumor activity and safety in sarcoma patients at a dose of 3.6 mg/kg administered every 14 days, with no significant responses observed in other advanced cancer patients at the same dose.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma

Daniel J. Olson, Zeynep Eroglu, Bruce Brockstein, Andrew S. Poklepovic, Madhuri Bajaj, Sunil Babu, Sigrun Hallmeyer, Mario Velasco, Jose Lutzky, Emily Higgs, Riyue Bao, Timothy C. Carll, Brian Labadie, Thomas Krausz, Yuanyuan Zha, Theodore Karrison, Vernon K. Sondak, Thomas F. Gajewski, Nikhil Khushalani, Jason J. Luke

Summary: This study is the first prospective study in melanoma of pembrolizumab plus low-dose ipilimumab after anti-PD-1/L1 immunotherapy failure, demonstrating significant antitumor activity and tolerability.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Review Immunology

High Throughput Multi-Omics Approaches for Clinical Trial Evaluation and Drug Discovery

Jessica M. Zielinski, Jason J. Luke, Silvia Guglietta, Carsten Krieg

Summary: High throughput single cell multi-omics platforms have enabled unprecedented insights into biological and clinical questions, creating whole atlases of cell types and interaction networks. Combining different -omic workflows on a single cell level can help examine cellular phenotypes and immune effector functions, as well as accelerate cellular biomarker discovery and definition of druggable target pathways. Challenges in the field include sharing disruptive technologies to scientific communities while incorporating new approaches like genomic cytometry and single cell metabolomics.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Article Immunology

Case Report: Single Dose Anti-PD1 in a Patient With Metastatic Melanoma and Cardiac Allograft

Amy E. Goodman, Lilit Karapetyan, Melissa Pugliano-Mauro, Joshua E. Levenson, Jason J. Luke

Summary: This case study highlights the potential benefits of immune-checkpoint inhibition in cardiac transplant recipients with metastatic melanoma, suggesting that even a single dose of pembrolizumab may lead to significant clinical benefit without graft rejection. It also supports the idea that shorter or individualized dosing strategies for checkpoint inhibitors may be as effective as continuous treatment, based on translational and clinical evidence.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

PSMA targeted armored chimeric antigen receptor (CAR) T-cells in patients with advanced mCRPC: A phase I experience.

Matthew H. Carabasi, Meredith McKean, Mark N. Stein, Michael Thomas Schweizer, Jason J. Luke, Vivek Narayan, Russell Kent Pachynski, Rahul Atul Parikh, Jingsong Zhang, Thomas J. Fountaine, Jamie Rosen, Pam Hufner, Whitney Gladney, Karen Chagin

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

Characterization of liver function tests (LFTs) following tebentafusp (tebe) in previously treated (2L+) metastatic uveal melanoma (mUM) patients (pts).

Takami Sato, Richard D. Carvajal, Joseph J. Sacco, Alexander Noor Shoushtari, Jessica Cecile Hassel, Alexandra Ikeguchi, Leonel Fernando Hernandez-Aya, Paul Nathan, Matthew Rioth, Omid Hamid, Josep M. Piulats, Jason J. Luke, Douglas Buckner Johnson, Serge Leyvraz, Enrique Espinosa, Shaad Essa Abdullah, Daniel Sum, Sarah Lockwood, Patricia Mendez, Marcus O. Butler

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in patients (pts) with previously treated (2L+) metastatic uveal melanoma (mUM).

Richard D. Carvajal, Takami Sato, Marcus O. Butler, Joseph J. Sacco, Alexander Noor Shoushtari, Jessica Cecile Hassel, Alexandra Ikeguchi, Leonel Fernando Hernandez-Aya, Matthew Rioth, Omid Hamid, Josep M. Piulats, Jason J. Luke, Douglas Buckner Johnson, Serge Leyvraz, Enrique Espinosa, Laura Collins, Michelle L. McCully, Sarah Lockwood, Shaad Essa Abdullah, Paul Nathan

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

Phase I experience with first in class TnMUC1 targeted chimeric antigen receptor T-cells in patients with advanced TnMUC1 positive solid tumors.

Rodolfo Gutierrez, Payal D. Shah, Omid Hamid, Alfred L. Garfall, Avery Posey, Michael Russell Bishop, George R. Blumenschein, Melissa Lynne Johnson, Sylvia Lee, Jason J. Luke, Daniel Morgensztern, Thomas J. Fountaine, Rebecca Dryer-Minnerly, Saltanat Najmi, Pam Hufner, Karen Chagin

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma

Riyue Bao, Stefani Spranger, Kyle Hernandez, Yuanyuan Zha, Peter Pytel, Jason J. Luke, Thomas F. Gajewski, Samuel L. Volchenboum, Susan L. Cohn, Ami Desai

Summary: Tumor-infiltrating CD8(+) T cells and neoantigens are predictors of a favorable prognosis and response to immunotherapy in adult cancer, but their roles in pediatric malignancies are not well understood. In high-risk neuroblastoma, a T cell-inflamed signature is associated with improved survival, while higher neoantigen load is also linked to better outcomes. Additionally, certain transcriptional programs such as MYCN, ASCL1, SOX11, and KMT2A are inversely correlated with T cell inflammation and may be potential targets for immune-potentiating interventions.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Review Oncology

STING Agonists as Cancer Therapeutics

Afsaneh Amouzegar, Manoj Chelvanambi, Jessica N. Filderman, Walter J. Storkus, Jason J. Luke

Summary: Immunotherapies have significantly impacted cancer treatment, yet some patients do not respond effectively. Recent efforts have been focused on identifying targets that could enhance anti-tumor immune responses, with STING pathway being one novel and promising target. Research on STING agonists has opened avenues for developing more effective strategies in cancer immunotherapy.

CANCERS (2021)

添加到收藏夹

Review Oncology

Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy

Claudia Trojaniello, Jason J. Luke, Paolo A. Ascierto

Summary: Melanoma, the most fatal skin cancer, has seen a significant revolution in treatment since 2011 with targeted therapy and immunotherapy. Current research focuses on preventing resistance, increasing drug effectiveness, and exploring new treatment combinations and targets to benefit more patients.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers

Brian W. Labadie, Arjun V. Balar, Jason J. Luke

Summary: Immune checkpoint inhibitors (ICI) have provided significant clinical benefit in genitourinary malignancies, especially in renal cell and urothelial carcinoma, but a large fraction of patients do not benefit from them. Identification of patient and tumor-derived factors associated with response has helped in understanding the mechanisms of response and resistance to ICI.

CANCERS (2021)

添加到收藏夹

Article Oncology

Evaluation of Dose Distribution to Organs-at-Risk in a Prospective Phase 1 Trial of Pembrolizumab and Multisite Stereotactic Body Radiation Therapy (SBRT)

Annie Xiao, Jason J. Luke, Julien Partouche, Ted Karrison, Steven J. Chmura, Hania A. Al-Hallaq

Summary: The purpose of this study was to characterize the radiation doses to organs-at-risk (OAR) in patients undergoing stereotactic body radiation therapy (SBRT) combined with programmed cell death protein 1 blockade for metastatic disease. The results showed that multisite SBRT could be safely tolerated when treating critical OAR near NRG-BR001 constraints, with acceptable toxicity in the corresponding organ systems.

PRACTICAL RADIATION ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

Intratumoral injection of SYNB1891, a synthetic biotic designed to activate the innate immune system, demonstrates target engagement in humans including intratumoral STING activation.

Filip Janku, Jason J. Luke, Aoife Brennan, Richard Riese, Mary Varterasian, Michael B. Armstrong, Karen L. Kuhn, Anna Sokolovska, James F. Strauss

CANCER RESEARCH (2021)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.